News & articles

September 2, 2014 Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA). Click here to read more.

September 1, 2014 I know that it seems like there’s a month or day for everything, from Hamburger Day to Dental Hygienist Appreciation Week, but there are really good reasons to have a month for Blood Cancer Awareness, particularly if you have Polycythemia Vera, Essential Thrombocythemia or Myelofibrosis. There are many people who don’t recognize… Read More »SEPTEMBER IS BLOOD CANCER AWARENESS MONTH

August 5, 2014 CTI BioPharma has been granted Fast Track designation by the FDA for pacritinib for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are not as… Read More »FDA GRANTS FAST TRACK DESIGNATION TO CTI BIOPHARMA’S PACRITINIB, A NOVEL JAK2 INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS

July 31, 2014 The MPN Research Foundation has joined forces with a coalition of patient advocacy organizations who seek to reduce the disparity in copays for people on specialty medication. The initiative, called Cap the Copay,  is working to fix what we see as a disparately high copay for people who must take specialty tier medication… Read More »2014 MPNRF JOINS CAP THE COPAY INITIATIVE IN ILLINOIS

July 30, 2014 Following up on the discovery of a new genetic mutation for MPNs, several institutions now have CALR diagnostic tests available, including the BloodCenter of Wisconsin. Click here to read the full article. Read more about the CALR discovery

July 29, 2014 The Agency for Toxic Substances and Disease Registry (ATSDR) recently released more data following their study of a Polycythemia Vera cluster that was found in the Tri-County area in Pennsylvania. Click here to read the report. More information on the PV cluster: Questions remain on the PV cluster (May 2011)Report on community screening (May 2010)Latest… Read More »2014 ATSDR ANNOUNCES MORE FINDINGS FROM PV CLUSTER IN PENNSYLVANIA

John Crispino, PhD, Scientific Advisor If it’s summer, it’s time for two important meetings where researchers present their latest findings on MPNs: In the US, it’s the American Society of Clinical Oncology (ASCO) meeting, and in Europe it’s the European Hematology Association Meeting (EHA). Here’s a brief summary of key findings: PRM-151 shows promising results… Read More »2014 SUMMER SCIENCE UPDATE

July 1 2014 The MPN Research Foundation and The Leukemia & Lymphoma Society (LLS) are proud to announce that ten new research projects will receive funding through their collaboration, renamed MPN Challenge™ in 2014. Winners of these one year grants focus on five areas, selected during 2013’s MFC Forum meeting of academia and industry convened… Read More »2014 MPN CHALLENGE GRANTS AWARD $1 MILLION IN RESEARCH FUNDING

June 23, 2014 The Stem Cell Physiopathology group at the CNIC (the Spanish National Cardiovascular Research Center), led by Dr. Simón Méndez–Ferrer has shown that the micro-environment of the bone marrow is a good target for therapeutic options for people with myeloproliferative neoplasms. Click here for the letter, recently published in Nature, or click here for… Read More »2014 CNIC DISCOVERS EXPANDED ROLE OF BONE MARROW MICRO-ENVIRONMENT FOR MPNS

June 12, 2014 Geron Corp. announced today that the FDA has removed the partial clinical hold on its clinical trial of imetelstat in myelofibrosis. The hold for polycythemia vera and essential thrombocythemia remails. Cick here for the full story. Previous reports on Imetelstat: Geron’s Imetelstat put on partial clinical hold for MF trials Telomerase Inhibitor Imetelstat… Read More »FDA REMOVES HOLD ON IMETELSTAT TRIALS IN MF